{"entity":{"id":"nct03850574","kind":"trial","name":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","aka":["TUSCANY"],"tldr":"A phase 1/2 trial of Venetoclax and Azacitidine in myelodysplastic syndromes / neoplasms and chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Aptose Biosciences Inc., now recruiting.","summary":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT03850574 by Aptose Biosciences Inc., with 240 participants planned, started 2019-03-11 and due to reach its primary completion in 2026-11. Interventions recorded: Tuspetinib, Venetoclax Oral Tablet and Azacitidine for Intravenous Infusion.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03850574","url":"https://clinicaltrials.gov/study/NCT03850574"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mds","cmml"],"sections":[],"technologies":[],"targets":[],"drugs":["venetoclax","azacitidine","tuspetinib"],"companies":["aptose"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03850574","phase":"1/2","setting":"A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)","sponsor":"Aptose Biosciences Inc.","participation":[{"nct":"NCT03850574","source":"https://clinicaltrials.gov/study/NCT03850574","fetchedAt":"2026-10-07T16:53:10.205Z","studySha256":"5e5820983809db1cd126072d31cf9138b9835be1bae0fa83ea70a82f754034f5","overallStatus":"RECRUITING","lastUpdatePosted":"2025-08-26","leadSponsor":"Aptose Biosciences Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":240,"enrolmentType":"ESTIMATED","siteCount":34,"recruitingSiteCount":10,"countries":["Australia","Germany","New Zealand","South Korea","Spain","United States"]}],"started":"2019-03-11","startedType":"actual","enrolled":240,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03850574/","neighbours":{"cancer":[{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"tuspetinib","kind":"drug","name":"Tuspetinib","route":"/drugs/tuspetinib/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"aptose","kind":"company","name":"Aptose Biosciences","route":"/companies/aptose/"}]}}